AssetMark Inc
GPCR icon

AssetMark Inc’s Structure Therapeutics GPCR Stock Holding History

AssetMark Inc’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Buy
2,726
+182
+7% +$8.05K ﹤0.01% 1526
2026
Q1 		$123K Buy
2,544
+449
+21% +$30.7K ﹤0.01% 1480
2025
Q4 		$146K Sell
2,095
-289
-12% -$11.8K ﹤0.01% 1380
2025
Q3 		$66.8K Sell
2,384
-493
-17% -$9.82K ﹤0.01% 1538
2025
Q2 		$59.7K Buy
2,877
+820
+40% +$18K ﹤0.01% 1507
2025
Q1 		$35.6K Sell
2,057
-214
-9% -$5.24K ﹤0.01% 1526
2024
Q4 		$61.6K Buy
2,271
+953
+72% +$33.8K ﹤0.01% 1368
2024
Q3 		$57.8K Buy
1,318
+719
+120% +$27.8K ﹤0.01% 1255
2024
Q2 		$23.5K Buy
+599
New +$24.6K ﹤0.01% 1358

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

AssetMark Inc's GPCR Position: Q2 2026 in Review

AssetMark Inc increased its Structure Therapeutics (GPCR) stake by 7.2% in Q2 2026, buying an estimated $8.05K and bringing the position to 2,726 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

AssetMark Inc first reported a position in GPCR in Q2 2024 and has held it in 9 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • AssetMark Inc held 2,726 shares of Structure Therapeutics worth $146K as of Q2 2026.
  • AssetMark Inc bought 182 Structure Therapeutics shares in Q2 2026, an estimated $8.05K.
  • Structure Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1526 holding.
  • AssetMark Inc first reported a position in Structure Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.